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Abstract
Background: Amyotrophic lateral sclerosis (ALS) is a progressive and fatal neurodegenerative disorder of the human motor
system. Neuroinﬂammation appears to be an important modulator of disease progression in ALS. Speciﬁcally, reduction of regulatory
T cell (Treg) levels, along with an increase in pro-inﬂammatory effector T cells, macrophage activation and upregulation of co-
stimulatory pathways have all been associated with a rapid disease course in ALS. Autologous infusion of expanded Tregs into
sporadic ALS patients, resulted in greater suppressive function, slowing of disease progression and stabilization of respiratory
function. Tecﬁdera (dimethyl fumarate) increases the ratio of anti-inﬂammatory (Treg) to proinﬂammatory T-cells in patients with
relapsing remitting multiple sclerosis and rebalances the regulatory: inﬂammatory axis towards a neuroprotective phenotype.
Consequently, the aim of this study was to assess the efﬁcacy, safety, and tolerability of Tecﬁdera in sporadic ALS.
Methods:The study is an investigator led Phase 2multi-center, randomized, placebo controlled, double blind clinical trial assessing
the efﬁcacy and safety of Tecﬁdera in patients with sporadic ALS. The study duration is 40 weeks, with a 36-week study period and
end of study visit occurring at 40 weeks or at early termination/withdrawal from study. The TEALS study has been registered with the
Australian and New Zealand Clinical Trials registry (ANZCTR) under the trials registration number ACTRN12618000534280 and has
been approved by the Human Research Ethics Committee and Research Governance Ofﬁce at the lead site (Westmead Hospital)
with the ethics number HREC/17/WMEAD/353. The participating sites have obtained site speciﬁc ethics and governance approvals
from the local institution.
Results:The primary endpoint is slowing of disease progression as reﬂected by the differences in the ALS Functional Rating Score-
Revised (ALSFRS-R) score at Week 36. The secondary endpoints will include effects in survival, lower motor neuron function,
respiratory function, quality of life and safety.
Conclusion: This Phase 2 multi-center, randomized, placebo controlled, double blind clinical trial will provide evidence of efﬁcacy
and safety of Tecﬁdera in sporadic ALS.
Abbreviations: AE = adverse event, ALS = amyotrophic lateral sclerosis, ALSFRS-R = ALS functional rating score-revised,
ALSSQOL-R= ALS SpeciﬁcQuality of Life Revised, ALT= alanine aminotransferase, AST= aspartate aminotransferase, BMI= body
mass index, CI = chief investigator, CMAP = compound muscle action potential, CRO = clinical research organization, CSF =
cerebrospinal ﬂuid, DMF = dimethyl fumarate, DML = distal motor latency, DSMB = data safety management board, ELISA =
enzyme-linked immunosorbent assay, FVC = forced vital capacity, ICF = informed consent form, IEC = independent ethics
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committee, IFN-g = interferon-g, IL = interleukin, ITT = intent-to-treat, ME = maximal expiratory pressure, MI = maximal inspiratory
pressure, MRC =medical research council, NI = neurophysiological index, PI = principle investigator, PP = per protocol population,
SAE = serious adverse event, SAF = safety population, SAP = statistical analysis plan, SI = split hand index, SNIP = sniff nasal
inspiratory pressure, SOD-1 = superoxide dismutase one, TEALS = Tecﬁdera in ALS study, Tregs = regulatory T cells, ULN = upper
limit of normal.
Keywords: ALS, ASLFRS-R, neuroimmunity, TECFIDERA, Treg
1. Introduction
Amyotrophic lateral sclerosis (ALS) is a progressive and fatal
neurodegenerative disorder of the human motor system, with
median survival of 3 to 5 years.[1,2] The currently licensed
treatments for ALS include riluzole [anti-glutamatergic agent][3–5]
and edaravone,[6] both of which provide limited beneﬁts. The
etiology of sporadic ALS remains unresolved, although a complex
multistep interaction between genetic and molecular processes,
along with environmental inﬂuences, seems likely.[2,7,8] Over the
past several decades there have been more than 250 separate
clinical studies searching for an effective treatment forALS,noneof
which were successful in slowing the progression of ALS.[9,10]
There is accumulating evidence for a role of neuroinﬂamma-
tion in ALS pathogenesis, with astrocytes, microglia and T cells
actively contributing to neurodegeneration and disease progres-
sion in ALS.[11–16] Speciﬁcally, reduced expression of mutant
superoxide dismutase one (SOD1) protein in microglia[17] and
astrocytes[18] has been associated with a slower rate of disease
progression. In addition, elimination of functional CD4+ T cells
accelerates the rate of disease progression in SOD1 mouse
models, a process that can be rectiﬁed by reconstitution of the
immune system through bone marrow transplantation.[12,19]
Importantly, upregulation of regulatory T cells (CD4+FoxP3+
Tregs) in blood and lymph node tissue was reported in the early
disease stages of the SOD1 mouse model, with increased
expression of FoxP3 mRNA, a key transcriptional regulator of
Tregs, evident in the spinal cord.[20] In addition, upregulation of
anti-inﬂammatory cytokines (interleukin [IL]-4, IL-10) is also
evident in the early stages of disease resulting in a neuroprotective
microglia (M2) phenotype which provides neurotrophic sup-
port.[13] With disease progression, there is upregulation of
proinﬂammatory cytokines IL-1b, IL-6 and interferon-g [IFN-g])
along with expansion of the CD4+CD25 T effector levels,
decline in Treg and transition of the microglia to a neurotoxicM1
phenotype.[13] Interestingly, adoptive transfer of Tregs into
SOD1 mouse models induces the M2 phenotype and prolongs
survival,[13,21] thereby suggesting that Tregs may be neuro-
protective in ALS by modulating microglial activation. Of further
relevance, expansions of the effector population in the SOD-1
mouse model by IL2 treatment was associated with reduced
disease progression, prolonged survival and preservation of
motor neuron size and dendritic networks,[22] underscoring a
potential therapeutic effect of an immune modulating approach.
Neuroinﬂammation also appears to be a key modulator of
disease progression in ALS patients.[15,22] A reduction of Treg
levels, alongwith an increase in pro-inﬂammatory effector T cells,
increased macrophage activation and upregulation of co-
stimulatory pathways have been associated with a rapid disease
course in ALS patients.[23–28] Of relevance, rapidly progressive
ALS patients express a reduced level of FoxP3 mRNA in the
spinal cord along with an increase in peripheral monocytes
expressing pro-inﬂammatory genes.[15,29] Taken together, these
ﬁndings suggest that the immune balance is skewed to a more
proinﬂammatory state in ALS patients with a rapidly progressive
disease course. Importantly, autologous infusion of expanded
Tregs into sporadic ALS patients, resulted in greater suppressive
function, slowing of disease progression and stabilization of
respiratory function,[30] underscoring the therapeutic potential of
the Treg based neuromodulatory approach in ALS.
Enhancement of Treg levels in humans can be achieved safely
and effectively by using dimethyl fumarate (tecﬁdera), a
commercially available medication for treatment of the relaps-
ing-remitting form of multiple sclerosis.[31,32] In relapsing
remitting multiple sclerosis patients, tecﬁdera was shown to
increase the ratio of anti-inﬂammatory to proinﬂammatory T-cell
subsets.[33,34] Tecﬁdera also results in stabilization of Treg
frequency and a concomitant reduction in pro-inﬂammatory T-
cells [CD4+ INFg+; CD8+ INFg+],[33] underscoring its potency in
rebalancing the regulatory: inﬂammatory axis towards a neuro-
protective phenotype. Consequently, the aim of the current Phase
II randomized placebo controlled multicenter trial was to assess
the efﬁcacy and safety of tecﬁdera in sporadic ALS. Current
manuscript publishes the trial protocol (version 3.0) which has
been approved by the ethics committee.
2. Methods
2.1. Aims and objectives
The primary aim of this clinical trial as to assess the efﬁcacy of
tecﬁdera (dimethyl fumarate, DMF) on disease progression in
sporadic ALS patients. The secondary aim of this study is to assess
effects of tecﬁdera in sporadic ALS patients on survival, lower
motor neuron dysfunction, respiratory dysfunction, quality of life
as well as safety and tolerability. The primary and secondary aims
of thiswill be achieved throughamulti-center, randomized,double-
blind, placebo controlled clinical trial conducted on sporadic ALS
patients that will be prospectively recruited from 6 ALS centers in
Australia. The total study duration will be 40 weeks, with a 36-
week studyperiodandanendof studyvisit occurringat 40weeksor
at early termination/withdrawal from study.
2.2. Primary outcome measure
The primary outcome measure is slowing of disease progression
as reﬂected by the differences in the ALS Functional Rating Score-
Revised (ALSFRS-R) score at Week 36 between active and
placebo groups. The ALSFRS-R is a validated rating instrument
for monitoring the progression of disability in patients with ALS
and is utilized for monitoring functional change in ALS patients.
The score assesses various 4 domains including:
(i) bulbar function (speech, salivation, swallowing);
(ii) ﬁne motor task (handwriting, cutting food and handling
utensils, with or without gastrostomy, dressing and hygiene);
(iii) gross motor task (turning in bed, walking, climbing stairs);
(iv) respiratory function (dyspnea, orthopnea and respiratory
insufﬁciency).[35]
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Each item within a domain is attributed a score of 0 (complete
loss of function) to 4 (normal), yielding a maximum score of 48
when the function is preserved. The ALSFRS-R will be measured
at screening, baseline, week 12, 24, 36, and 40.
2.3. Secondary outcome measures
The secondary outcome measures will be measured at screening,
baseline, week 12, 24, 36 and 40. The secondary endpoints will
include measures of efﬁcacy and safety.
1. Survival
Survival will be deﬁned from symptom onset to death of
patients or tracheostomy insertion, whichever occurs ﬁrst and
will be measured in months.
2. Lower motor neuron function
Lower motor neuron function will be assessed by clinical
and neurophysiological biomarkers and will included muscle
strength and motor amplitudes.-Muscle strength
(a) Medical Research Council score: Clinical assessment of
muscle strength will be made by theMedical Research Council
(MRC) score. The MRC score is a standard clinical score used
in clinical practice and will be performed by the neurologist at
each site. This score assesses muscle strength on a 5-point score
as follows:
 5=Normal strength.
 4=Active movement against gravity and resistance.
 3=Weak contraction against gravity.
 2=Active movement with gravity eliminated.
 1=Minimal contraction.
 0=Complete paralysis.
The following movements will be assessed in each patient:
-Upper limbs: Shoulder abduction, elbow ﬂexion, elbow
extension, wrist extension, ﬁnger extension, ﬁnger abduction,
and thumb abduction on both sides. The total score when
strength normal in the upper limbs will be 70.
-Lower limbs: Hip ﬂexion, abduction, adduction and
extension, knee ﬂexion and extension, and ankle dorsiﬂexion
and plantarﬂexion. The total score when strength is normal in
the lower limbs will be 80. The upper and lower limb MRC
scores will be combined yielding a maximum score of 150 (0
severe weakness to 150 normal strength).
(b) Hand dynamometry: Muscle strength will also be
assessed by hand-held dynamometry (JAMAR PLUS, Patter-
son Medical, Warrenville, IL). A spring-loaded device that
“breaks” at pre-set forces will be used to assess readings
obtained by hand-held dynamometry throughout the study.
Wherever possible, the same rater will be used at each site for
each assessment. Grip strength dynamometry for both hands
will be acquired, and the mean force in kilograms will be
calculated. Measures will be obtained from each hand in
triplicate
-Neurophysiological testing: The degree of lower motor
neuron loss will be determined neurophysiological testing
performed on nerve conduction study machines (Nicolet EDX,
System, Natus, Middleton, WI). The following parameters
will be recorded from the intrinsic hand muscles on both
sides.
(a) Neurophysiological Index (NPI): This is an established
measure of lower motor neuron dysfunction in ALS.[36] The
NPI will be calculated from by stimulating the median
nerve at the wrist and recording the motor response from
the abductor pollicis brevis muscle using the following
formula:
NPI ¼ CMAP amplitude  Fwave frequency=DML
Where CMAP is the compound muscle action potential,
DML is distal motor latency and F-wave frequency is the
number of F-wave that occur with 10 consecutive supra-
threshold stimulations.
(b) Split Hand Index (SI): The split hand index as an
objective biomarker of the split hand phenomenon, an
important clinical feature of ALS.[37–39] The SI will be
calculated as follows:
SI ¼ CMAP amplitude APB  CMAP amplitude FDI=CMAP amplitude ADM
3. Respiratory function
Respiratory function will be assessed by using speciﬁc
respiratory function tests.
-Forced vital capacity (FVC): Forced expiratory volume
(FEV) measures how much air a person can exhale during a
forced breath. The amount of air exhaled may be measured
during the ﬁrst (FEV1), second (FEV2), or third seconds
(FEV3) of the forced breath. Forced vital capacity (FVC) is the
total amount of air exhaled during the FEV test. The deﬁnition
of FVC is therefore, the amount of air which can be forcibly
exhaled from the lungs after taking the deepest breath
possible. For measuring FVC the patient will be instructed to
inhale deeply and exhales completely while in a standing
position. Results of the test will be recorded and analyzed by
the spirometry machine (Welch-Allyn) and interpreted by the
PI. Three trials will be performed and the best FVC result (%of
predicted) will be recorded.
-Sniff nasal inspiratory pressure (SNIP): The SNIP is the
measurement of pressure through an occluded nostril during
sniffs performed through the contralateral nostril. It is an
accurate and non-invasive approximation of oesophageal
pressure swing during sniff manoeuvres. Respiratory strength
is assessed by measuring the maximal inspiratory pressure
(MIP or PImax) and the maximal expiratory pressure (MEP or
PEmax). The MIP reﬂects the strength of the diaphragm as well
as other inspiratory and expiratory muscles.
4. Urinary neurotrophin receptor P75 level
The urinary neurotrophin receptor p75 is a biomarker of
neurodegeneration measured by an enzyme-linked immuno-
sorbent assay (ELISA).[40] Speciﬁcally, the ELISA test
measures the extracellular portion of the neurotrophin
receptor p75 that is cleaved from neurons in ALS. Neuro-
trophin receptor p75 is increased in serum, CSF and urine of
ALS patients, although urinary measures are preferable. With
disease progression in ALS, there is an increase in neurotrophic
p75 levels.[41,42]
Urinary neurotrophic receptor p75 levels will be measured
according to the following protocol:
 The test will be performed on diluted urine and will be
performed in triplicate in 4 separate assays. The mean value
is calculated from the 12 measurements.
 Urinary dilution is accounted for by correcting with
creatinine and the level of p75 (ng) will be provided per
mg of creatinine.
 A mid-stream urine sample will be collected into a sterile
urine container.
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 The urine samples will undergo urinalysis (SIEMENS
Multistix 10 SG) and samples with abnormal readings
(high glucose, pH > 8, positive for leucocytes or blood) will
be discarded. Eligible urine samples 10–50mL) will be
centrifuged at 2000g (4°C) for 5 minutes. A 1mL aliquot
will be collected, placed in secure tube, labeled and stored at
80°C within 4 hours of collection) until transported to the
ALS Biomarker Centre at Flinders University for analysis.
5. ALS Speciﬁc Quality of Life Revised (ALSSQOL-R)
The ALSQuality of Life Revised is a validated questionnaire
that will be used to assess the impact of tecﬁdera on the
patients quality of life.[43] The ALSSQOL-R is a 50-item
disease-speciﬁc questionnaire covering multiple domains.
Each question is scored from 0 (not at all) to 10 (very much)
yielding a total score range from 0 to 500. The questionnaire
can be completed bymost ALS patients in approximately 15 to
20 minutes.
6. Assessment of Safety
The Investigators and study site staff will be responsible for
documentation of events meeting the deﬁnition of an adverse
event (AE) or serious adverse event (SAE). Adverse events will
be deﬁned any unfavorable and unintended consequence
(including an abnormal laboratory ﬁnding), symptom, or
disease (new or exacerbated) temporally associated with
the use of tecﬁdera, whether or not considered related to the
medicinal product. Disease progression of ALS will not
be considered an AE. The potential AEs related to tecﬁdera are
highlighted in Table 1.
Serious adverse events are deﬁned as any event that results in
death, disability or incapacity, is life threatening, or leads to
congenital abnormality/birth defect. Hospitalization for any
medical event, other than elective surgery, will also be deemed an
SAE. All opportunistic infections and malignancies will be
considered as SAEs. The investigator will make an assessment of
the seriousness and causality of each AE and SAE.
2.4. Patient enrolment and withdrawal
Sample size calculation: Based on previous clinical studies and
literature,[44,45] it was assumed that the mean difference in the
ASLFRS-R score between active and placebo group at 36 weeks
will be 7 [common standard deviation of 8%]. A clinically
important response rate on Tecﬁdera was deﬁned as 0.9, andwith
a 2:1 (Tecﬁdera:Placebo) allocation, 90% power, 5% statistical
signiﬁcance rate and 20% dropout rate, we estimated that 90
patients (60:30) need to be randomized inorder to attain the
primary outcome measure. The inclusion and exclusion criteria
are outlined in Table 2.
3. Study design
Investigator led Phase II multi-center, randomized, placebo
controlled, double blind clinical trial assessing the efﬁcacy and
safety of Tecﬁdera in patients with sporadic ALS. Study
procedures will be performed as detailed in the Schedule of
Events Flow Chart in Table 3.
3.1. Screening Visit (Visit 1) -14 days
Patients will be screened for the study after signing an approved
Informed Consent Form (ICF). As part of the screening, patient’s
extensive medical and neurological history will be recorded.
Inclusion/exclusion criteria will be evaluated and the vital signs
(blood pressure, pulse, temperature, and respiratory rate) will be
recorded. Physical and neurological examinations will be
performed. Patient’s height and weight will be measured and
body mass index (BMI) will be calculated. The visit will also
involve an initial assessment of ALSFRS-R, NPI and SI, FVC as
measured by handheld spirometer, SNIP test, quantitative hand
muscle testing by dynamometry, and global strength using MRC
score. Prior/ongoing medications will be recorded. All patients
will undergo laboratory evaluation of hematological and
biochemical parameters; hepatitis B, C, and human immunodeﬁ-
ciency virus (HIV) serology; and urinalysis. In addition, women
of childbearing potential will undergo a urine pregnancy test.
Urine will also be collected for neurotrophin receptor P75 levels
(secondary outcome). An ALSSQOL-R questionnaire will be
completed by the patient at screening.
3.2. Baseline (Visit 2) Week 0 (14 days post visit 1)
All patients will have their inclusion and exclusion criteria
checked at the Baseline Visit (Week 0) and eligible patients will be
Table 1
Adverse reactions reported with tecﬁdera.
Frequency
MedDRA System Organ Class Very Common (≥1%) Less Common (≥0.1% to <1%)
Infections and Infestations Gastroenteritis (associated with lymphopenia <0.5109 cells/L)
Blood and Lymphatic System Disorders Lymphopenia, Leucopenia
Nervous System Disorders Burning sensation
Vascular Disorders Flushing Hot Flush
Gastrointestinal Disorders Diarrhea Vomiting
Nausea Dyspepsia
Abdominal Pain Upper Gastritis
Abdominal Pain Gastrointestinal disorder
Skin and Subcutaneous Tissue Disorders Pruritus
Rash
Erythema
Renal and Urinary Disorders Proteinuria, albuminuria
General Disorders and Administration Site Conditions Feeling hot
MedDRA=Medical Dictionary for Regulatory Activities. A rare adverse effect of tecﬁdera reported in relapsing remitting multiple sclerosis patients is progressive multifocal leukoencephalopathy (PML). Progressive
multifocal leukoencephalopathy is an opportunistic viral infection of the brain that may lead to death or severe disability. The risk of developing PML while on Tecﬁdera treatment is extremely rare (<1:10,000).
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randomized to either active group (Tecﬁdera) or control group
(placebo) in a 2:1 ratio and the IP will be dispensed.
Randomization will be performed by a third party (Cenduit)
working with the CRO, using an Interactive Web Response
System with random number generation. The numbers will be
emailed to a designated pharmacist at each sit and bottles will be
labeled by the randomly generated number. All parties at each site
will be blinded, and unblinding will only occur after data
analysis. This study visit will also involve an assessment of
ALSFRS-R, vital signs (blood pressure, pulse rate, temperature,
and respiratory rate), and any changes to concomitant
medications. Urine samples will be collected for safety monitor-
ing (urinalysis). In addition, women of childbearing potential will
undergo another urine pregnancy test.
3.3. Treatment Period (Visits 3, 4, and 5) Weeks 12, 24,
and 36
Patients will return to the site at Weeks 12, 24, and 36 for
neurological and physical examinations. Their weight, BMI, and
vital signs (blood pressure, pulse, temperature, and respiratory
rate) will be recorded. The visit will also involve an assessment of
ALSFRS-R, NPI and SI, FVC as measured by handheld
spirometer, SNIP test, quantitative hand muscle testing by
dynamometry, and global strength as measured by the MRC
score. All patients will undergo laboratory evaluation of
hematological and biochemical parameters as well as urinalysis.
In addition, women of childbearing potential will undergo a urine
pregnancy test and urine will also be collected to test neuro-
trophin receptor P75 levels (secondary endpoint). If the patient
consented for additional research in future, blood samples
(additional) will be collected for storage. At Week 12 and 36, an
ALSSQOL-R questionnaire will be completed by patients and the
IP will be dispensed at Week 12 and Week 24.
3.4. End of Study (Visit 6) Week 40
After completing Week 36 procedures, all patients will return to
the study site at Week 40 for the End of Study Visit (4 weeks after
the end of treatment visit). Patients who discontinue the study
early will be asked to return to the study site for the early
termination procedures 4 weeks after their last dose of Tecﬁdera/
placebo. At this visit, neurological and physical examination will
be performed and vital signs (blood pressure, pulse, temperature,
and respiratory rate) will be recorded. The visit will also involve
an assessment of ALSFRS-R, NPI and SI, FVC as measured by
handheld spirometer, SNIP test, quantitative hand muscle testing
by dynamometry, and global strength using MRC score. All
patients will undergo laboratory evaluation of hematological and
biochemical parameters as well as urinalysis. Urine will also be
collected to test neurotrophin receptor P75 levels (secondary
endpoint). An ALSSQOL-R questionnaire will also be completed
by all patients. Adverse events and changes to concomitant
medications will be observed and evaluated.
Table 2
The inclusion and exclusion criteria for TEALS study.
Inclusion criteria Exclusion criteria
Male and female patients aged 18 to 85 years at the time of the
Screening Visit
Dependence on mechanical ventilation at the time of screening
Sporadic ALS diagnosed as deﬁnite, probable, or possible according
to the Awaji criteria
Gastrostomy at the time of Screening/Baseline Visit. If the patient has a gastrostomy tube
inserted post randomisation they will be allowed to continue in the study
Able to provide informed consent and comply with study procedures Participation in any other clinical trial or using an investigational product within the last 12 weeks
prior to screening
Disease duration at recruitment less than 24 months from diagnosis Known hypersensitivity to Tecﬁdera or any excipients in this product
Patient must have the results of magnetic resonance imaging scan of
brain and spinal cord undergone within 2 years prior to the
Screening Visit
Presence of a monogenic cause of ALS
Forced vital capacity >60% of predicted value as adjusted for
gender, height, and age at the Screening Visit
Taking immunosuppressive medications
If taking Riluzole, must be on a stable dose of riluzole for at least 30
days prior to the Screening Visit
Unstable medical disease (such as unstable angina, heart failure, chronic obstructive pulmonary
disease, liver disease, or renal disease), or active infectious disease (such as hepatitis B or C
or tuberculosis, HIV), or current malignancy
Women of childbearing potential must have a negative urine
pregnancy test at screening and Baseline, and be surgically sterile
or postmenopausal, or using highly effective methods of
contraception throughout the study and for 30 days after the last
dose of drug
Unstable psychiatric illness deﬁned as psychosis or untreated major depression within 90 days of
the Screening Visit. Dementia as previously diagnosed by a medical practitioner
Safety Laboratory Criteria at the Screening Visit:
-Alanine aminotransferase (ALT) >3 the upper limit of normal (ULN).
-Total bilirubin, lactate, triglycerides, amylase, or lipase >2 the ULN.
-Patient has impaired renal function deﬁned as creatinine clearance of <40mL/min via Cockroft-
Gault method.
-Absolute neutrophil count of <2109/L.
-Absolute lymphocyte count of <0.5109/L.
-Platelet concentration of <100109/L.
-Hemoglobin <100 g/L.
Female patients who are pregnant, lactating, or intend to become pregnant during the study
period
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3.5. Safety monitoring
An independent data safety management board (DSMB) will
oversee the safety aspects of this study. The DSMB will also
include independent specialist physicians from different medical
subspecialties. The DSMB will periodically examine the safety
data emerging from the study and provide its recommendations
to the chief investigator (CI) who will then pass these onto the
independent ethics committee (IEC). The roles and responsibili-
ties of the DSMB, their operational procedures, and method of
communication with the CI will be described in a separate DSMB
charter. Members of DSMB will not be investigators in the study
nor will they have any conﬂict of interest with the CI.
The clinical trial may be prematurely suspended or terminated
if, in the opinion of the DSMB or PIs, there is reasonable cause.
Written notiﬁcation, documenting the reason for study suspen-
sion or termination, will be provided by the suspending or
terminating party. The pertinent regulatory authorities will be
informed according to the national regulations.
Circumstances that may warrant termination include:
 Determination of unexpected, signiﬁcant, or unacceptable risk
to patients.
 Insufﬁcient adherence to protocol requirements.
 Data that are not sufﬁciently complete and/or evaluable.
 Plans to modify, suspend, or discontinue the development of
the IP.
If the study is prematurely terminated or suspended, the CI will
promptly inform the site-speciﬁc PIs, their institutions, and the
regulatory authority of the termination or suspension and
the reason(s) for the termination or suspension. The IEC will also
be informed promptly and provided the reason(s) for the
termination or suspension by the Sponsor or by the CI/institution,
as speciﬁed by the applicable regulatory requirement(s).
Patients will be free to withdraw from the study at any time for
any reason without penalty to their continuing medical care. In
addition, patients must bewithdrawn from the study by the site PI
in consultation with the CI for the following reasons:
 Grade 4 clinical adverse events considered causally related to
Tecﬁdera.
 Allergic or anaphylactic reactions to IP.
 Development of severe lymphopenia (persistent lymphocyte
count <0.5109cells/L, for 8 weeks).
 Pregnancy.
 Compliance failure.
 Protocol violation.
Table 3
Schedule of events for the TEALS study.
Schedule of Events Study Procedures Screening Baseline Visit Treatment Period
End of Study/Early
Termination
Week (±7 days) –14 days Week 0 W 12 W 24 W 36 Week 40
Study Visit 1 2 3 4 5 6
Informed Consent X
Demographics X
Medical and Family History X
Height, Weight, and Body Mass Index
∗
X X X X X
Physical Examination X X X X X
Neurological Examination X X X X X
Vital Signs† X X X X X X
Inclusion/Exclusion Criteria Assessment X X
Dispense IP X X X
ALSFRS-R X X X X X X
Hepatitis B and C, HIV serology‡ X
Hematology X X X X X
Biochemistryx X X X X X
Blood sample collection for storage (for additional Biomarker
analysis in future)jj
Xjj Xjj Xjj Xjj Xjj
Neurotrophin receptor p75 extracellular domain (p75ECD) X X X X X
Urinalysis X X X X X X
Urine Pregnancy¶ X X X X X
Neurophysiological Index (NPI) Split hand index (SI) X X X X X
Medical Research Council (MRC) Score X X X X X
Hand Dynamometry X X X X X
Forced Vital Capacity (FVC) X X X X X
Sniff Nasal Inspiratory Pressure (SNIP) Test X X X X X
Adverse Events X X X X X X
Prior and Concomitant medications X X X X X X
ALSSQOL-R (Quality of Life Questionnaire) X X X X
ALSFRS-R= amyotrophic lateral sclerosis functional rating score-revised, ALSSQOL-R= amyotrophic lateral sclerosis speciﬁc quality of life revised, HIV=human immunodeﬁciency virus, IP= investigational
product, W=week.
∗
Height will be measured at Screening Visit only.
† Vital signs includes blood pressure, pulse, temperature, and respiratory rate.
‡ State/territory requirements will be followed for HIV and Hepatitis Serology testing.
x See Table 3 (Section 13.1.10) for tests to be performed under haematology and biochemistry panels.
jj For patients who have consented for additional research, blood samples (additional) will be collected at screening, Weeks 12, 24, 36, and 40 for storage (This is optional).
¶ Urine pregnancy test will be performed for female patients of childbearing potential only.
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 Serum creatinine >1.2upper limit of normal (ULN).
 Alanine aminotransferase (ALT) >5 ULN.
 Single aspartate aminotransferase (AST) >8 ULN.
 The ALT or AST levels >3 ULN for 4 consecutive weeks.
 ALT or AST >3ULN and (total bilirubin >2ULN).
 ALT or AST >3ULN with appearance of fatigue, nausea,
vomiting, right upper quadrant pain or tenderness, fever, rash,
and/or eosinophilia (>5%).
Every effort will be made to ensure that patients who do not
complete all study requirements return to the site for the Early
Termination Visit, 4 weeks after the last dose of IP. Patients who
withdraw due to an AE or SAE will be given appropriate care
under medical supervision until the symptoms resolve or the
patient’s condition becomes stable.
3.6. Statistical methods
The statistical analysis will be performed using statistical analysis
system (SAS) Version 9.4. All details regarding the statistical
analysis and the preparation of tables, listings, and ﬁgures will be
described in the Statistical Analysis Plan (SAP) and approved by
the Sponsor before database lock. The default summary statistics
for continuous variables include number of contributing
observations (n), mean, SD, median, minimum, and maximum.
For categorical variables, the number and percentage (in each
category will be the default summary presentation. “Baseline” is
deﬁned as the last observed value of the parameter of interest
prior to the ﬁrst intake of IP (this includes unscheduled visits). For
numerical variables, change from Baseline will be calculated as
the difference between the value of interest and the corresponding
Baseline value. All formal statistical tests will be two-sided at the
5% signiﬁcance level. Point estimates of treatment differences
will be accompanied with a two-sided 95% conﬁdence intervals.
In the case of normality assumption violations, appropriate non-
parametric methods will be used for analysis. All data will be
presented in by-patient listings.
The following analysis populations will be deﬁned as follows:
i. Intent-to-Treat (ITT) Population- The ITT population will
include all randomized patients. In this population, treatment
will be assigned based upon the treatment arm to which
patients were randomized regardless of which treatment they
received;
ii. Safety Population (SAF)- The SAF includes patients who are
randomized and took at least 1 dose of the IP. The safety
analysis will be conducted according to the treatment that a
patient actually receives;
iii. Per Protocol Population (PP)- The PP population will include
all patients who do not have major protocol deviations that
would affect the evaluation of the primary efﬁcacy endpoint.
The primary endpoint (ALSFRS-R change at 36 weeks) will
be analyzed using Mixed Model for Repeated Measures
with treatment as ﬁxed effect and Baseline ALSFRFS-R score
as covariate. For the active treatment versus placebo compari-
son, the results will be presented in terms of an estimated
treatment difference together with its associated 95% conﬁ-
dence intervals and 2-sided P value. Possible effects of
other covariates will also be investigated. Missing data
handling and possible sensitivity analysis will be described
in the SAP. Details of speciﬁc alternative statistical methods in
the event model assumptions are violated will be documented in
the SAP.
Efﬁcacy analysis for secondary endpoints (see outcome
measures section) will be summarized and evaluated using the
ITT population. Safety analyses will be performed using SAF. All
safety data will be provided in by-patient listings. The safety
variables that will be analyzed are outlined in Table 1. No interim
analysis is planned for the study. All statistical analysis has been
performed by the IQUVIA (CRO) biostatisticians in consultation
with the PIs (Vucic and Kiernan).
4. Ethics and dissemination
The TEALS study has been approved by the Human Research
Ethics Committee and Research Governance Ofﬁce at the lead
site (Westmead Hospital) with the ethics number HREC/17/
WMEAD/353. The participating sites have obtained site speciﬁc
ethics and governance approvals from the local institution. Any
protocol modiﬁcations will be communicated by the PI (SV) to
lead sites via email after ethics approval.
Patients, legally authorized representatives, caregivers or
responsible family members, may provide written consent on
the approved ICF. The PI or research staff designee will explain
all study procedures, risks, and alternative therapies to the
patient. The patient will have an opportunity to have all questions
answered. The appropriate parties will then sign and date the
ICF, indicating willingness to participate in the study. A copy of
the signed ICF will be given to the patient.
All data will be stored in a purpose-built data base for the
TEALS study. The data base was developed by the contract
research organization (IQUVIA) in consultation with the chief
and principle investigators. Upon completion of the study
(including data lock and analysis), unblinded data will be stored
for a minimum of 15 years on the database to which the CI and PI
will have access. The results will be disseminated by presentations
at neurology scientiﬁc meetings and through manuscript
publications in international neurology or medical journals.
The results will be published irrespective of whether the primary
and secondary endpoints are attained. All PIs will be authors on
the trial. The data set and statistics will be made available upon
reasonable request.
5. Trial registration
This study has been registered with the Australian and New
Zealand Clinical Trials registry (ANZCTR) under registration
number ACTRN12618000534280.
6. Trial status
The TEALS study commenced in October 2017 and is ongoing.
We anticipate that the results will be available in the last quarter
of 2020 or ﬁrst quarter of 2021.
7. Discussion
There is increasing evidence for an important role of neuro-
inﬂammation in regulating disease activity in ALS.[46] Regulatory
T cells appear to be important in regulating the rate of disease
progression in ALS,[13] as evidenced by signiﬁcant correlation
between the rates of disease progression and Treg levels,[13] as
well as neuroprotective effects exerted by Tregs in mouse models
of ALS.[28] In addition, reconstitution studies in mutant SOD1
muse models have also demonstrated that CD4+ T cells improve
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neurological function and prolong survival, with the events being
most evident when Tregs were passively transferred, thereby
implying an important neuroprotective role for the Treg
subsets.[12,13,19,21]
In ALS patients, memory effector Tregs (CD45RO+) levels
exhibit signiﬁcant correlations with the rates of disease
progression.[22] These ﬁndings suggest that the functional
capacity of Tregs to induce immunosuppression is critical for
reducing the rates of disease progression in ALS. Importantly,
autologous infusion of expanded Tregs (which exhibit normal
suppressive function) into ALS patients resulted in a slowing of
disease progression and stabilization of respiratory function.[30]
Given that Tecﬁdera can enhance Treg levels in patients with
relapsing remitting multiple sclerosis,[33,34] the aim of the current
trial was to assess the efﬁcacy and safety of tecﬁdera in sporadic
ALS.
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